dosedrugsOnlineOfflineع
You're offline — running on data saved to your device.
curosurf 80mg/ml intratracheal susp. 3 ml
كيوروسيرف 80 مجم / مل معلق 3 مل
poractant alfa · 80mg/ml
4712EGP
Available
Active ingredient
poractant alfa
Strength
80mg/ml
Form
suspension
Manufacturer
chiesi > pharma over seas
Route
oral.liquid

Uses

Poractant alfa is a porcine-derived natural lung surfactant indicated for rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. It reduces mortality and the incidence of pneumothorax associated with RDS.

Do not use if

No absolute contraindications have been identified.

Side effects

Common adverse reactions include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation occurring transiently during administration. These are generally managed by temporarily interrupting the infusion.

Warnings

Administer only by trained personnel with immediate access to ventilatory support. Continuously monitor heart rate and oxygen saturation during administration. Rapidly adjust ventilator settings as lung compliance may change acutely after dosing.

How it works

Poractant alfa is a modified natural surfactant extracted from porcine lungs containing phospholipids and hydrophobic proteins (SP-B and SP-C). It replaces deficient endogenous surfactant in premature lungs, reduces alveolar surface tension during expiration, and prevents alveolar collapse, thereby improving lung compliance and gas exchange.

Storage

Refrigerate at 2–8°C. Protect from light. Unopened vials may be stored at room temperature (below 25°C) for up to 24 hours. Do not re-refrigerate after warming.